CEP250-AS1

Across TCGA pan-cancer cohorts, CEP250-AS1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of CEP250-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CEP250-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CEP250-AS1 is over-expressed in tumor, although a few such as LUSC and PAAD show the opposite, repressed pattern.

KIRC, LUSC, and KIRP are the cancer types where CEP250-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEP250-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.895	<.001	11	view →
LUSC	All	III,IV	−0.740	<.001	9	view →
KIRP	All	All	+0.307	.002	3	view →
LIHC	Female	All	+0.176	.023	3	view →
ESCA	All	II,III,IV	+1.130	.007	2	view →
PAAD	Male	All	−0.915	.039	2	view →
STAD	Female	All	+0.727	.030	2	view →
THCA	Male	IV	+0.516	.006	2	view →
BRCA	All	IV	−0.380	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

CEP250-AS1–KIRC

Open the KIRC breakdown →